tetano
Editor, Senior Moderator
Emerg Microbes Infect. 2018 Sep 12;7(1):153. doi: 10.1038/s41426-018-0154-6.
[h=1]A live attenuated vaccine prevents replication and transmission of H7N9 highly pathogenic influenza viruses in mammals.[/h] Yang W[SUP]1,[/SUP][SUP]2[/SUP], Yin X[SUP]2[/SUP], Guan L[SUP]2[/SUP], Li M[SUP]2[/SUP], Ma S[SUP]2[/SUP], Shi J[SUP]2[/SUP], Deng G[SUP]2[/SUP], Suzuki Y[SUP]3[/SUP], Chen H[SUP]4,[/SUP][SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] H7N9 influenza viruses emerged in 2013 and have caused severe disease and deaths in humans in China. Some H7N9 viruses circulating in chickens have mutated to highly pathogenic viruses that have caused several disease outbreaks in chickens. Studies have shown that when the H7N9 highly pathogenic viruses replicate in ferrets or humans, they easily acquire certain mammalian-adapting mutations and become highly lethal in mice and highly transmissible in ferrets by respiratory droplet, creating the potential for human-to-human transmission. Therefore, the development of effective control measures is a top priority for H7N9 pandemic preparedness. In this study, we evaluated the protective efficacy of a cold-adapted, live attenuated H7N9 vaccine (H7N9/AAca) against two heterologous H7N9 highly pathogenic viruses in mice and guinea pigs. Our results showed that one dose of the H7N9/AAca vaccine prevented disease and death in mice challenged with two different H7N9 highly pathogenic viruses, but did not prevent replication of the challenge viruses; after two doses of H7N9/AAca, the mice were completely protected from challenge with A/chicken/Hunan/S1220/2017(H7N9) virus, and very low viral titers were detected in mice challenged with H7N9 virus CK/SD008-PB2/627 K. More importantly, we found that one dose of H7N9/AAca could efficiently prevent transmission of CK/SD008-PB2/627 K in guinea pigs. Our study suggests that H7N9/AAca has the potential to be an effective H7N9 vaccine and should be evaluated in humans.
PMID: 30206210 PMCID: PMC6133968 DOI: 10.1038/s41426-018-0154-6
[h=1]A live attenuated vaccine prevents replication and transmission of H7N9 highly pathogenic influenza viruses in mammals.[/h] Yang W[SUP]1,[/SUP][SUP]2[/SUP], Yin X[SUP]2[/SUP], Guan L[SUP]2[/SUP], Li M[SUP]2[/SUP], Ma S[SUP]2[/SUP], Shi J[SUP]2[/SUP], Deng G[SUP]2[/SUP], Suzuki Y[SUP]3[/SUP], Chen H[SUP]4,[/SUP][SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] H7N9 influenza viruses emerged in 2013 and have caused severe disease and deaths in humans in China. Some H7N9 viruses circulating in chickens have mutated to highly pathogenic viruses that have caused several disease outbreaks in chickens. Studies have shown that when the H7N9 highly pathogenic viruses replicate in ferrets or humans, they easily acquire certain mammalian-adapting mutations and become highly lethal in mice and highly transmissible in ferrets by respiratory droplet, creating the potential for human-to-human transmission. Therefore, the development of effective control measures is a top priority for H7N9 pandemic preparedness. In this study, we evaluated the protective efficacy of a cold-adapted, live attenuated H7N9 vaccine (H7N9/AAca) against two heterologous H7N9 highly pathogenic viruses in mice and guinea pigs. Our results showed that one dose of the H7N9/AAca vaccine prevented disease and death in mice challenged with two different H7N9 highly pathogenic viruses, but did not prevent replication of the challenge viruses; after two doses of H7N9/AAca, the mice were completely protected from challenge with A/chicken/Hunan/S1220/2017(H7N9) virus, and very low viral titers were detected in mice challenged with H7N9 virus CK/SD008-PB2/627 K. More importantly, we found that one dose of H7N9/AAca could efficiently prevent transmission of CK/SD008-PB2/627 K in guinea pigs. Our study suggests that H7N9/AAca has the potential to be an effective H7N9 vaccine and should be evaluated in humans.
PMID: 30206210 PMCID: PMC6133968 DOI: 10.1038/s41426-018-0154-6